Hemorrhagic cystitis in a patient receiving gemtuzumab ozogamicin for relapsed acute promyelocytic leukemia after cord blood transplantation

被引：0
作者：
Akihide Yoshimi
Takashi Asai
Akira Hangaishi
Tsuyoshi Takahashi
Shigeru Chiba
Mineo Kurokawa
机构：
[1] University of Tokyo,Department of Hematology & Oncology, Graduate School of Medicine
来源：
Annals of Hematology | 2008年 / 87卷
关键词：
Herpes Simplex Virus; Hematopoietic Stem Cell Transplantation; Acute Promyelocytic Leukemia; Arsenic Trioxide; Gemtuzumab Ozogamicin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：851 / 852
页数：1
相关论文
共 50 条
  • [21] Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells
    Takeshita, A
    Shinjo, K
    Naito, K
    Matsui, H
    Sahara, N
    Shigeno, K
    Horii, T
    Shirai, N
    Maekawa, M
    Ohnishi, K
    Naoe, T
    Ohno, R
    LEUKEMIA, 2005, 19 (08) : 1306 - 1311
  • [22] Probable Veno-occlusive disease after treatment with gemtuzumab ozogamicin in a patient with acute myeloid leukemia and a history of liver transplantation for familial hemochromatosis
    O'Boyle, KR
    Murigeppa, A
    Jain, D
    Dauber, L
    Dutcher, JP
    Wiernik, PH
    MEDICAL ONCOLOGY, 2003, 20 (04) : 379 - 383
  • [23] Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia
    Abedin, Sameem M.
    Badar, Talha
    Gauger, Katelyn
    Michaelis, Laura C.
    Runaas, Lyndsey
    Carlson, Karen-Sue
    Murthy, G. S. Guru
    Atallah, Ehab
    LEUKEMIA RESEARCH, 2022, 123
  • [24] Probable veno-occlusive disease after treatment with gemtuzumab ozogamicin in a patient with acute myeloid leukemia and a history of liver transplantation for familial hemochromatosis
    Kevin P. O’Boyle
    Ashwin Murigeppa
    Dharamvir Jain
    Leonard Dauber
    Janice P. Dutcher
    Peter H. Wiernik
    Medical Oncology, 2003, 20 : 379 - 383
  • [25] Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia
    Wang, Eunice S.
    Aplenc, Richard
    Chirnomas, Deborah
    Dugan, Michael
    Fazal, Salman
    Iyer, Swaminathan
    Lin, Tara L.
    Nand, Sucha
    Pierce, Kristen J.
    Shami, Paul J.
    Vermette, Jennifer J.
    Abboud, Camille N.
    LEUKEMIA & LYMPHOMA, 2020, 61 (08) : 1965 - 1973
  • [26] Complete remission induced by gemtuzumab ozogamicin in a Jehovah's witness patient with acute myelogenous leukemia
    Fujisawa, Shinya
    Naito, Kensuke
    Matsuoka, Toshihiko
    Kobayashi, Masahide
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2007, 85 (05) : 418 - 420
  • [27] Complete Remission Induced by Gemtuzumab Ozogamicin in a Jehovah’s Witness Patient with Acute Myelogenous Leukemia
    Shinya Fujisawa
    Kensuke Naito
    Toshihiko Matsuoka
    Masahide Kobayashi
    International Journal of Hematology, 2007, 85 : 418 - 420
  • [28] Two Patients with All -trans Retinoic Acid-Resistant Acute Promyelocytic Leukemia Treated Successfully with Gemtuzumab Ozogamicin as a Single Agent
    Akihiro Takeshita
    Kaori Shinjo
    Kensuke Naito
    Hirotaka Matsui
    Naohi Sahara
    Kazuyuki Shigeno
    Taeko Suzumura
    Toshinobu Horii
    Naohito Shirai
    Masato Maekawa
    Yoshihiro Yada
    Hirofumi Teshima
    Jin Takeuchi
    Kazunori Ohnishi
    Ryuzo Ohno
    International Journal of Hematology, 2005, 82 : 445 - 448
  • [29] Prolonged molecular remission after autologous stem cell transplantation in relapsed acute promyelocytic leukemia
    Ferrara, F
    Palmieri, S
    Annunziata, M
    Pocali, B
    Viola, A
    Pane, F
    HAEMATOLOGICA, 2004, 89 (05) : 621 - 622
  • [30] Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia
    Buckwalter, M
    Dowell, JA
    Korth-Bradley, J
    Gorovits, B
    Mayer, PR
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (08) : 873 - 880
12345